Bristol Myers Squibb’s Admilparant Meets Phase 3 Trial Primary Endpoint
Bristol Myers Squibb said its 52-week phase 3 trial of twice-daily admilparant in adults with idiopathic pulmonary fibrosis met its primary endpoint.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.